Obermatt
See Similar Stocks →

Xenon Pharmaceuticals

NMQ:XENE · CA98420N1050
BiotechnologySmall

360

28
Medium confidence — indicative
Profit price50
Owner Earnings Yield1
Dividend Yield1
Price/Sales4
Price/Book44
Return on Capital34
Cash Return on Capital37
Return on Equity38
Profit margins14

Cash truth not applicable for financial companies.

Sales growth6
Profit Growth8
Long-Term EPS Growth16
Reinvestment51
Price momentum54
Debt load82
Refinancing61
Debt Payback1
Liquidity37
Analyst ratings69
Opinion Changes50
Price Target Upside55
Market mood52
Value Creation6/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Xenon Pharmaceuticals doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryCanada
IndustryBiotechnology
SizeSmall
TypePublic Company
ExchangeNASDAQGM
Founded1996
Employees371
Websitexenon-pharma.com
ISINCA98420N1050
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Pain ManagementPsychiatryGeneticsCentral Nervous SystemNeurologyNeuroscienceBiopharmaMedicalPharmaceutical

Description

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need. The company is advancing a differentiated produ…

Analysis

Middle-of-the-road

Xenon Pharmaceuticals Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is tepid and the balance sheet is adequate. The company scores 6/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
25
2026

All-time high

37

Mar 2026

All-time low

25

Jun 2026

Average rank

31

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
4
—
—
—
Price/Earnings
75
—
—
—
Price/Book
44
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
13
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Xenon Pharmaceuticals with its peers
Tharimmune
NAQ:THAR
—
CountryUSA
IndustryBiotechnology
SizeX-Small
Full Stock Analysis →
Bright Minds Biosciences
CNX:DRUG
88
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Tonix Pharmaceuticals
NAQ:TNXP
37
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Cytokinetics
NSQ:CYTK
13
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Atea Pharmaceuticals
NSQ:AVIR
5
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
RAPT Therapeutics
NMQ:RAPT
—
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →